Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration

British Journal of Pharmacology

Volumn 162, Issue 6, 2011, Pages 1225-1238

  Sabbadini, Roger A ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

age related macular degeneration; antibody therapeutics; cancer; choroidal neovascularization; ocular disease; retinal pigmented epithelial cells; S1P; Sphingosine 1 phosphate; wet AMD

Indexed keywords

BEVACIZUMAB; CYTOTOXIC AGENT; FINGOLIMOD; LT 1002; MONOCLONAL ANTIBODY; RANIBIZUMAB; SONEPCIZUMAB; SPHINGOMAB; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE ANTIBODY; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; EXUDATIVE MACULAR DEGENERATION; FIBROSIS; GEOGRAPHIC ATROPHY; HUMAN; IATROGENIC DISEASE; INFLAMMATION; INFUSION RELATED REACTION; LIGAND BINDING; LIPID BLOOD LEVEL; LYMPHOCYTOPENIA; MELANOMA; MOLECULAR INTERACTION; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SUBRETINAL NEOVASCULARIZATION; THERMOSTABILITY; TOXICITY TESTING; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; HUMANS; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE; WET MACULAR DEGENERATION;

EID: 79951981180     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01118.x     Document Type: Review

References (125)

1. Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S, (2010). Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina 30: 1420-1425.
2. Ader I, Malavaud B, Cuvillier O, (2009). When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy. Cancer Res 68: 8635-8642.
3. Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR, (2007). In vivo models of proliferative vitreoretinopathy. Nat Protoc 2: 67-77. (Pubitemid 47040070)
4. Alderton F, Rakhit S, Kong KC, Palmer T, Sambi B, Pyne S, et al. (2001). Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells. J Biol Chem 276: 28578-28585. (Pubitemid 37391573)
5. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, et al. (2004). Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279: 52487-52492. (Pubitemid 39656625)
6. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. (2010). Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465: 1084-1088.
7. An S, Goetzl EJ, Lee H, (1998). Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophosphatidic acid and sphingosine 1-phosphate. J Cell Biochem Suppl 30-31: 147-157. (Pubitemid 29028736)
8. Anliker B, Chun J, (2004). Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 15: 457-465. (Pubitemid 38953942)
9. Argraves KM, Wilkerson BA, Argraves WS, Fleming PA, Obeid LM, Drake CJ, (2004). Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J Biol Chem 279: 50580-50590. (Pubitemid 39577875)
10. 2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 278: 32841-32851. (Pubitemid 37055726)
11. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S, Geilen CC, (2005a). Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24: 178-187. (Pubitemid 40143877)
12. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S, (2005b). A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 169: 801-811. (Pubitemid 41002885)
13. Beljanski V, Knaak C, Smith CD, (2010). A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 333: 454-464.
14. Birgbauer E, Chun J, (2006). New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 63: 2695-2701. (Pubitemid 44913311)
15. Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, et al. (2010). Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 109: 1232-1243.
16. Bora NS, Kaliappan S, Jha P, Xu Q, Sohn JH, Dhaulakhandi DB, et al. (2006). Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol 177: 1872-1878. (Pubitemid 44092526)
17. Caballero S, Swaney J, Moreno K, Afzal A, Kielczewski J, Stoller G, et al. (2009). Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp Eye Res 88: 367-377.
18. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, et al. (2009). Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest 119: 1871-1879.
19. Chae SS, Paik JH, Furneaux H, Hla T, (2004). Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 114: 1082-1089. (Pubitemid 39578697)
20. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, et al. (2003). Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63: 5446-5453. (Pubitemid 37139863)
21. Colombaioni L, Garcia-Gil M, (2004). Sphingolipid metabolites in neural signalling and function. Brain Res Brain Res Rev 46: 328-355. (Pubitemid 39574333)
22. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803. (Pubitemid 26243122)
23. Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, et al. (2010). Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 3: 53-65.
24. Cyster JG, (2004). Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127-159.
25. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, et al. (2010). The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 192: 314-324.
26. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962-5969. (Pubitemid 37187498)
27. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD, (2006). Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318: 596-603. (Pubitemid 44061234)
28. Fukuoka Y, Medof EM, (2001). C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res 23: 320-325. (Pubitemid 34264319)
29. Fyrst H, Saba JD, (2010). An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol 6: 489-497.
30. Gardell SE, Dubin AE, Chun J, (2006). Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12: 65-75. (Pubitemid 43202124)
31. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA, (2009). Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res 82: 303-312.
32. Goetzl EJ, Graeler M, Huang MC, Shankar G, (2002). Lysophospholipid growth factors and their G protein-coupled receptors in immunity, coronary artery disease, and cancer. ScientificWorldJournal 2: 324-338.
33. Goparaju SK, Jolly PS, Watterson KR, Bektas M, Alvarez S, Sarkar S, et al. (2005). The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol 25: 4237-4249. (Pubitemid 40617669)
34. Gordon MS, Just R, Rosen LS, Dorr A, (2010). A phase 1 study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors. J Clin Oncol 28: (No 15S Part 1 of 2): 219s.
35. Graler MH, Goetzl EJ, (2004). The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 18: 551-553.
36. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, et al. (2008). Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a 'come-and-get-me' signal. FASEB J 22: 2629-2638.
37. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S, (2006). Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 1758: 2016-2026. (Pubitemid 44879368)
38. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. (2009). Regulation of histone acetylation in the nucleus by sphingosine-1- phosphate. Science 325: 1254-1257.
39. He S, Jin ML, Worpel V, Hinton DR, (2003). A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization. Arch Ophthalmol 121: 1283-1288. (Pubitemid 37128406)
40. He X, Huang CL, Schuchman EH, (2009). Quantitative analysis of sphingosine-1-phosphate by HPLC after napthalene-2,3-dicarboxaldehyde (NDA) derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 877: 983-990.
41. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, et al. (2006). Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113: 633 e1- e4.
42. Hla T, (2004). Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 15: 513-520. (Pubitemid 38953947)
43. Ho JW, Man K, Sun CK, Lee TK, Poon RT, Fan ST, (2005). Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4: 1430-1438.
44. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, et al. (2001). Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science 291: 1800-1803. (Pubitemid 32198987)
45. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T, (2003). VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 100: 10664-10669. (Pubitemid 37140085)
46. Im DS, (2009). New intercellular lipid mediators and their GPCRs: an update. Prostaglandins Other Lipid Mediat 89: 53-56.
47. Ishibashi T, Inomata H, Sakamoto T, Ryan SJ, (1995). Pericytes of newly formed vessels in experimental subretinal neovascularization. Arch Ophthalmol 113: 227-231.
48. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, et al. (2005). Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 59: 1159-1166. (Pubitemid 41262984)
49. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, et al. (2009). Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69: 6915-6923.
50. Katsuma S, Ruike Y, Yano T, Kimura M, Hirasawa A, Tsujimoto G, (2005). Transcriptional regulation of connective tissue growth factor by sphingosine 1-phosphate in rat cultured mesangial cells. FEBS Lett 579: 2576-2582. (Pubitemid 40615661)
51. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20: 386-388. (Pubitemid 46671180)
52. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, et al. (2007). Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 170: 281-292. (Pubitemid 47339207)
53. Lamontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, et al. (2006). Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231. (Pubitemid 43166028)
54. Langlois S, Gingras D, Beliveau R, (2004). Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 103: 3020-3028. (Pubitemid 38451675)
55. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. (1999a). Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99: 301-312. (Pubitemid 29519909)
56. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, et al. (1999b). Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264: 743-750.
57. Lepley D, Paik JH, Hla T, Ferrer F, (2005). The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res 65: 3788-3795. (Pubitemid 40616357)
58. Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, (2008a). Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 88: 11-17.
59. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, Pitson SM, et al. (2008b). Basal and angiopoietin-1-mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 111: 3489-3497.
60. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. (2009). Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 15: 1393-1399.
61. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. (2008). FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111: 275-284.
62. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, et al. (2010). Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol 30: 3827-3841.
63. Lucas da Silva LB, Ribeiro DA, Cury PM, Cordeiro JA, Bueno V, (2008). FTY720 treatment in experimentally urethane-induced lung tumors. J Exp Ther Oncol 7: 9-15. (Pubitemid 351521213)
64. Lucke S, Levkau B, (2010). Endothelial functions of sphingosine-1- phosphate. Cell Physiol Biochem 26: 87-96.
65. Maceyka M, Payne SG, Milstien S, Spiegel S, (2002). Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 1585: 193-201. (Pubitemid 36096858)
66. Maceyka M, Milstien S, Spiegel S, (2005). Sphingosine kinases, sphingosine-1-phosphate and sphingolipidomics. Prostaglandins Other Lipid Mediat 77: 15-22. (Pubitemid 41133411)
67. Maines LW, French KJ, Wolpert EB, Antonetti DA, Smith CD, (2006). Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases. Invest Ophthalmol Vis Sci 47: 5022-5031. (Pubitemid 46586409)
68. Melendez AJ, Ibrahim FB, (2004). Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca2+ signals, enzyme release, cytokine production, and chemotaxis. J Immunol 173: 1596-1603. (Pubitemid 38971589)
69. Melendez AJ, Carlos-Dias E, Gosink M, Allen JM, Takacs L, (2000). Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 251: 19-26. (Pubitemid 30339413)
70. Michaud J, Im DS, Hla T, (2010). Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 184: 1475-1483.
71. Milstien S, Spiegel S, (2006). Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. Cancer Cell 9: 148-150. (Pubitemid 43357940)
72. Moolenaar WH, (1999). Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238.
73. Murata N, Sato K, Kon J, Tomura H, Okajima F, (2000a). Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem 282: 115-120. (Pubitemid 30409432)
74. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. (2000b). Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 352 Pt 3: 809-815. (Pubitemid 32015038)
75. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al. (2007). FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117: 2408-2421. (Pubitemid 47494343)
76. O'Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, et al. (2009). Production and characterization of monoclonal anti-sphingosine-1- phosphate antibodies. J Lipid Res 50: 2245-2257.
77. Olivera A, Rivera J, (2005). Sphingolipids and the balancing of immune cell function: lessons from the mast cell. J Immunol 174: 1153-1158.
78. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, et al. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147: 545-558.
79. Paik JH, Chae S, Lee MJ, Thangada S, Hla T, (2001). Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem 276: 11830-11837.
80. Paik JH, Skoura A, Chae SS, Cowan AE, Han DK, Proia RL, et al. (2004). Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev 18: 2392-2403. (Pubitemid 39304686)
81. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, et al. (2008). A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112: 1382-1391.
82. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, et al. (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 7: 1836-1845.
83. Petrukhin K, (2007). New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets 11: 625-639. (Pubitemid 46744687)
84. Puneet P, Yap CT, Wong L, Lam Y, Koh DR, Moochhala S, et al. (2010). SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis. Science 328: 1290-1294.
85. Pushparaj PN, H'Ng SC, Melendez AJ, (2008). Refining siRNA in vivo transfection: silencing SPHK1 reveals its key role in C5a-induced inflammation in vivo. Int J Biochem Cell Biol 40: 1817-1825.
86. Pyne NJ, Pyne S, (2010). Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-503.
87. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH, (2004). G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 92: 949-966. (Pubitemid 44264244)
88. Raguz S, Yague E, (2008). Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99: 387-391.
89. Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, et al. (2009). A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest Ophthalmol Vis Sci 50: 3056-3064.
90. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, et al. (2008). Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112: 41-52.
91. Sabbadini RA, (2006). Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer 95: 1131-1135. (Pubitemid 44658473)
92. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J, (2003). Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3578-3585. (Pubitemid 36909798)
93. Sanchez T, Hla T, (2004). Structural and functional characteristics of S1P receptors. J Cell Biochem 92: 913-922. (Pubitemid 44264241)
94. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, et al. (2003). Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 278: 47281-47290. (Pubitemid 37452317)
95. Schmid G, Guba M, Papyan A, Ischenko I, Bruckel M, Bruns CJ, et al. (2005). FTY720 inhibits tumor growth and angiogenesis. Transplant Proc 37: 110-111. (Pubitemid 40459705)
96. Shida D, Fang X, Kordula T, Takabe K, Lepine S, Alvarez SE, et al. (2008a). Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 68: 6569-6577.
97. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S, (2008b). Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 9: 662-673.
98. Lucas da Silva LB, Ribeiro DA, Cury PM, Cordeiro JA, Bueno V, (2008). FTY720 treatment in experimentally urethane-induced lung tumors. J Exp Ther Oncol 7: 9-15.
99. Skoura A, Hla T, (2009). Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res 82: 221-228.
100. Skoura A, Sanchez T, Claffey K, Mandala SM, Proia RL, Hla T, (2007). Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest 117: 2506-2516. (Pubitemid 47494352)
101. Spiegel S, Milstien S, (2003). Sphingosine-1-phosphate: an enigatic signalling lipid. Mol Cell Biol 4: 397-407.
102. Stamer WD, Read AT, Sumida GM, Ethier CR, (2009). Sphingosine-1-phosphate effects on the inner wall of Schlemm's canal and outflow facility in perfused human eyes. Exp Eye Res 89: 980-988.
103. TM, an anti-sphingosine-1-phosphate (Anti-S1P) monoclonal antibody for investigation in exudative AMD: results from a phase 1 prospective open-label dose-escalating multi-center study. Invest Ophthalmol Vis Sci 51: E-Abstract 1253.
104. Swaney JS, Moreno KM, Gentile AM, Sabbadini RA, Stoller GL, (2008). Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp Eye Res 87: 367-375.
105. Taha TA, Hannun YA, Obeid LM, (2006). Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131.
106. Takuwa Y, (2002). Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta 1582: 112-120. (Pubitemid 34634119)
107. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, et al. (2009). S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 85: 484-493.
108. Tanimoto T, Jin ZG, Berk BC, (2002). Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 277: 42997-43001. (Pubitemid 35285679)
109. Teicher B, (2011). Antiangiogenic agents and targets: a perspective. Biochem Pharmacol 81: 6-12.
110. Tsutsumi C, Sonoda KH, Egashira K, Qiao H, Hisatomi T, Nakao S, et al. (2003). The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 74: 25-32. (Pubitemid 38040433)
111. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW, (2005). Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64: 695-705. (Pubitemid 41177111)
112. Vinores SA, Seo MS, Okamoto N, Ash JD, Wawrousek EF, Xiao WH, et al. (2000). Experimental models of growth factor-mediated angiogenesis and blood-retinal barrier breakdown. Gen Pharmacol 35: 233-239. (Pubitemid 34215115)
113. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. (2006). Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9: 225-238. (Pubitemid 43357948)
114. Vlasenko LP, Melendez AJ, (2005). A critical role for sphingosine kinase in anaphylatoxin-induced neutropenia, peritonitis, and cytokine production in vivo. J Immunol 174: 6456-6461. (Pubitemid 40663840)
115. Weigert A, Weis N, Brune B, (2009). Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology 214: 748-760.
116. Wojciak JM, Zhu N, Schuerenberg KT, Moreno K, Shestowsky WS, Hiraiwa M, et al. (2009). The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen. Proc Natl Acad Sci USA 106: 17717-17722.
117. Xia P, Gamble J, Wang L, Pitson SM, Moretti PA, Wattenberg BW, et al. (2000). An oncogenic role of sphingosine kinase. Curr Biol 10: 1527-1530. (Pubitemid 32003646)
118. Xie B, Shen J, Dong A, Rashid A, Stoller G, Campochiaro PA, (2009). Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol 218: 192-198.
119. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, et al. (2004). Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J Biol Chem 279: 35255-35262. (Pubitemid 39100522)
120. Yamagishi S, Imaizumi T, (2005). Pericyte biology and diseases. Int J Tissue React 27: 125-135. (Pubitemid 41723729)
121. Yamanaka M, Shegogue D, Pei H, Bu S, Bielawska A, Bielawski J, et al. (2004). Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem 279: 53994-54001. (Pubitemid 40053131)
122. Yasui K, Palade PT, (1995). Sphingolipid action on sodium and calcium currents of rat ventricular myocytes. Am J Physiol 270: C645-C649.
123. Yatomi Y, (2006). Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des 12: 575-587.
124. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, et al. (2000). Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96: 3431-3438.
125. Zhu D, Sreekumar PG, Hinton DR, Kannan R, (2009). Expression and regulation of enzymes in the ceramide metabolic pathway in human retinal pigment epithelial cells and their relevance to retinal degeneration. Vision Res 50: 643-651.